Hyperinflation SystemMarket Size, Share & Industry Analysis, By Device Type (Manual, Automatic), By Indication (Hypoxia, Preterm Births, Chronic Pulmonary Obstructive Disease (COPD)), By End-user (Hospitals & Clinics, Ambulatory Surgical Centres, Others) And Regional Forecast, 2024-2032

Hyperinflation therapy is used in patients that are affectd with any kind of respiratory distress. Hypeinflation systems are used in order to relieve the patient of this distress by supplying a greater volume of air to inflate the lungs.There are predominantly mannual nd automation inflation devices. Usually a respiratory therapist decides which type of hyperinfation would be suitable for a pateint. The rise in the incidence of various respiratory diseases usch as SARS, MERS and COVID-19 is projected to augument the market growth in the coming years.

The rising prevalence of zoonotic as well as other respiratory infectious disease is projected to favor the market growth in the coming years. For instance, according to the World Health Organization (WHO), the approximate incidence of pneumonia is 0.37 cases per year in children. Globally, more than 800,000 children died due to pneumonia in 2017. Additionally, outbreak of disease such as coronavirus is estimated to increase the adoption and use of hyperinflation devices in healthcare settings. All these factors combined with others are anticipated to significantly augment the market growth of hyperinflation systems in the coming years.

However, limited usability and tediousness in the use of manual hyperinflation device is estimated to restrain the market growth over the forecast duration.

Market Segmentation:

Globally, the Hyperinflation System market can be categorized among the vaccine type, disease indication, pathogen type, demographic, and region. Among the segmentation of vaccine type, the market can be categorized into monovalent Hyperinflation Systems and multivalent Hyperinflation Systems. Based on the segmentation of disease indication the market can be divided into pneumococcal, meningococcal, DTP, Influenza and others. On the basis of pathogen, the market can be segmented into viral Hyperinflation System, bacterial Hyperinflation System, and combination vaccines. Segmentation of demographic includes adult and pediatric.

Geographically, the Hyperinflation System market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the Hyperinflation System market are Vyaire Medical Inc., Teleflex medical Corporation, Smiths Medical, Mercury Medical, SunMed, Medline Industries, Medical Dynamics, Inc. and other prominent players.

Key Insights:

• Key Industry Developments – Merger, Acquisitions, and Partnerships


• Key Product Launches


• Overview of Regulatory Scenario – Key Country/Region


• COVID-19 Impact on Hyperinflation System Market

Regional Analysis:

Based on segmentation of region, the hyperinflation system market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is poised to dominate the market by gaining majority share. Factors such as increased preference for U.S FDA approvals among companies coupled with higher availability of hyperinflation devices in the region is estimated to drive the market in North America in the coming years. In Europe, the market is augmented by components such as increase used of hyperinflation devices in the region, increasing prevalence of respiratory illness and favorable healthcare insurance policies. However, the market in Asia Pacific is driven by factors such as rising geriatric population, increasing outbreaks of respiratory diseases and evolving healthcare infrastructure. Latin America and Middle East and Africa is estimated to capture a smaller share in the market attributed to lower product penetration in the regions.

Segmentation

Hyperinflation System Market Industry Developments

• In July 2019, the U.S FDA issued MAUDE adverse event report of BREATHTECH HYPERINFLATION SYSTEM, marketed by SunMed Holdings LLC. The report indicated that the device was damaged prior to use in a patient.


• In April 2020, the U.S FDA issued a update of potential risks involved with the use of hyperinflation system, ReShape liquid-filled intragastric balloons used for weight loss in adult patients with obesity.